News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
282,269 Results
Type
Article (14931)
Company Profile (299)
Press Release (267033)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (79952)
Career Advice (168)
Deals (13362)
Drug Delivery (39)
Drug Development (50716)
Employer Resources (31)
FDA (5848)
Job Trends (5182)
News (145258)
Policy (10086)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (921)
Accelerated approval (19)
Adcomms (14)
Allergies (85)
Alliances (21792)
ALS (126)
Alzheimer's disease (1035)
Antibody-drug conjugate (ADC) (244)
Approvals (6044)
Artificial intelligence (267)
Autoimmune disease (119)
Automation (9)
Bankruptcy (105)
Best Places to Work (4567)
BIOSECURE Act (6)
Biosimilars (101)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (46)
Breast cancer (348)
Cancer (3163)
Cardiovascular disease (239)
Career advice (153)
Career pathing (8)
CAR-T (224)
CDC (5)
Cell therapy (577)
Cervical cancer (14)
Clinical research (43732)
Collaboration (1168)
Company closure (2)
Compensation (603)
Complete response letters (41)
COVID-19 (1101)
CRISPR (87)
C-suite (565)
Cystic fibrosis (112)
Data (4359)
Denatured (15)
Depression (93)
Diabetes (256)
Diagnostics (1383)
Digital health (13)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (196)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (218)
Earnings (31741)
Editorial (27)
Employer branding (4)
Employer resources (29)
Events (51780)
Executive appointments (629)
FDA (7615)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (10)
Frontotemporal dementia (22)
Funding (991)
Gene editing (184)
Generative AI (22)
Gene therapy (496)
GLP-1 (507)
Government (1149)
Grass and pollen (3)
Guidances (166)
Healthcare (6620)
HIV (18)
Huntington's disease (43)
IgA nephropathy (75)
Immunology and inflammation (194)
Immuno-oncology (43)
Indications (71)
Infectious disease (1211)
Inflammatory bowel disease (157)
Inflation Reduction Act (10)
Influenza (40)
Intellectual property (169)
Interviews (18)
IPO (7363)
IRA (13)
Job creations (873)
Job search strategy (135)
JPM (40)
Kidney cancer (9)
Labor market (23)
Layoffs (243)
Leadership (10)
Legal (1405)
Liver cancer (41)
Longevity (11)
Lung cancer (425)
Lymphoma (251)
Machine learning (24)
Management (7)
Manufacturing (380)
MASH (132)
Medical device (2670)
Medtech (2679)
Mergers & acquisitions (6631)
Metabolic disorders (733)
Multiple sclerosis (104)
NASH (13)
Neurodegenerative disease (233)
Neuropsychiatric disorders (70)
Neuroscience (1965)
Neurotech (1)
NextGen: Class of 2026 (2034)
Non-profit (867)
Now hiring (31)
Obesity (333)
Opinion (125)
Ovarian cancer (132)
Pain (103)
Pancreatic cancer (165)
Parkinson's disease (232)
Partnered (12)
Patents (306)
Patient recruitment (345)
Peanut (44)
People (26714)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15497)
Phase 2 (20316)
Phase 3 (12835)
Pipeline (3355)
Policy (91)
Postmarket research (853)
Preclinical (6541)
Press Release (30)
Prostate cancer (147)
Psychedelics (50)
Radiopharmaceuticals (239)
Rare diseases (660)
Real estate (1451)
Recruiting (12)
Regulatory (9932)
Reports (19)
Research institute (974)
Resumes & cover letters (19)
Rett syndrome (24)
RNA editing (21)
RSV (17)
Schizophrenia (125)
Series A (184)
Series B (140)
Service/supplier (1)
Sickle cell disease (77)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2007)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (340)
Venture capital (69)
Weight loss (174)
Women's health (26)
Worklife (2)
Date
Today (52)
Last 7 days (314)
Last 30 days (1169)
Last 365 days (17853)
2026 (1964)
2025 (18100)
2024 (20550)
2023 (22420)
2022 (26825)
2021 (27813)
2020 (23366)
2019 (16248)
2018 (11762)
2017 (13755)
2016 (11863)
2015 (14374)
2014 (10401)
2013 (7522)
2012 (7583)
2011 (7671)
2010 (7462)
Location
Africa (154)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18276)
Australia (3114)
California (7141)
Canada (1857)
China (784)
Colorado (249)
Connecticut (255)
Delaware (237)
Europe (39225)
Florida (912)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (400)
India (36)
Indiana (162)
Iowa (8)
Japan (228)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (740)
Massachusetts (5629)
Michigan (110)
Minnesota (250)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (33)
New Hampshire (21)
New Jersey (1658)
New Mexico (13)
New York (1775)
North Carolina (837)
North Dakota (6)
Northern California (3516)
Ohio (180)
Oklahoma (11)
Oregon (24)
Pennsylvania (1287)
Puerto Rico (9)
Rhode Island (26)
South America (215)
South Carolina (9)
Southern California (2831)
Tennessee (40)
Texas (925)
United States (23542)
Utah (97)
Virginia (137)
Washington D.C. (37)
Washington State (593)
West Virginia (1)
Wisconsin (46)
282,269 Results for "sangamo therapeutics inc.rss".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering
February 4, 2026
·
4 min read
Press Releases
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026
February 4, 2026
·
10 min read
Press Releases
Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call
October 31, 2025
·
1 min read
Press Releases
Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
December 19, 2025
·
6 min read
Press Releases
Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease
November 24, 2025
·
6 min read
Press Releases
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results
November 7, 2025
·
17 min read
Press Releases
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy
December 3, 2025
·
6 min read
Press Releases
Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call
August 1, 2025
·
1 min read
Gene therapy
Sangamo’s ‘Positive’ Phase I/II Data for Fabry Gene Therapy Opens Path to FDA
Isaralgagene civaparvovec is a “potential best-in-class gene therapy for Fabry disease,” according to analysts at H.C. Wainwright. Sangamo plans to use pivotal Phase I/II data to build an accelerated approval case for the asset.
June 24, 2025
·
3 min read
·
Tristan Manalac
Press Releases
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results
August 8, 2025
·
17 min read
1 of 28,227
Next
